NDA 219130 · Almatica
Escitalopram
Escitalopram Oxalate · Oral
Last checked: Nov 20, 2026Latest source record: Aug 29, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Aug 29, 2025
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
484
106 Phase 3, 29 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Escitalopram Oxalate" as an intervention, any sponsor and status, largest first.
First Affiliated Hospital of Zhejiang UniversityAcademic, hospital or other
NCT05480150 · 10,000 participants (planned) · Start Nov 1, 2021 · Primary completion Dec 31, 2026
Drug: Escitalopram Oxalate Tablets; Quetiapine Fumarate Tablets and 1 more · For: Major Depressive Disorder; Bipolar Disorder, Mixed; Affective; Disorder, Organic
Sites: Hangzhou, China
- Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)Pivotal-lookingCompleted
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT01360866 · 2,944 participants · Start Oct 2011 · Primary completion Apr 18, 2017
Drug: OPC-34712; Escitalopram and 5 more · For: Depressive Disorder; Depression; Depressive Disorder, Major and 2 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 142 sites in all
- Sequential Multiple Assignment Randomized Trial for Bipolar DepressionPivotal-lookingActive, not recruiting
Massachusetts General HospitalAcademic, hospital or other
NCT06433635 · 2,726 participants (planned) · Start Oct 1, 2024 · Primary completion Feb 28, 2030
Drug: Cariprazine; Aripiprazole/Escitalopram combination and 2 more · For: Bipolar I Disorder; Depression
Sites: Birmingham, Alabama; Bloomington, Indiana; Baltimore, Maryland · 18 sites in all
- International Study to Predict Optimised Treatment - in DepressionPivotal-lookingStatus unknown
BRC Operations Pty. Ltd.Industry
NCT00693849 · 2,688 participants (planned) · Start Sep 2008 · Primary completion Dec 2019
Drug: Escitalopram; Sertraline and 1 more · For: Major Depressive Disorder
Sites: Colton, California; Mission Viejo, California; Stanford, California · 20 sites in all
Peking UniversityAcademic, hospital or other
NCT02023567 · 2,400 participants (planned) · Start Nov 2013 · Primary completion Dec 2016
Drug: SSRIs · For: Depressive Disorder, Major
Sites: Beijing, China; Shijiazhuang, China; Dalian, China · 9 sites in all
- Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant TreatmentPivotal-lookingCompleted
H. Lundbeck A/SIndustry
NCT01838681 · 1,986 participants · Start Jun 2013 · Primary completion Jun 2016
Drug: Placebo; Brexpiprazole and 1 more · For: Major Depressive Disorder
Sites: Little Rock, Arkansas; Cerritos, California; Temecula, California · 107 sites in all
- SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension StudyPivotal-lookingTerminated
ShireTakeda (TAK)
NCT01436175 · 1,570 participants · Start Feb 27, 2012 · Primary completion Mar 27, 2014
Drug: SPD489 (Lisdexamfetamine dimesylate) + Antidepressant · For: Major Depressive Disorder
Sites: Birmingham, Alabama; Scottsdale, Arizona; Little Rock, Arkansas · 212 sites in all
- Improving Outcomes in Depression in Primary Care in a Low Resource SettingPivotal-lookingActive, not recruiting
Harvard Medical School (HMS and HSDM)Academic, hospital or other
NCT05944926 · 1,500 participants (planned) · Start Mar 18, 2024 · Primary completion Apr 10, 2026
Drug: Antidepressant medication (fluoxetine) · For: Depression; Depressive Disorder
Sites: Bhopal, India
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Mindfulness-Based Stress Reduction vs Escitalopram for the Treatment of Adults With Anxiety Disorders: A Randomized Clinical Trial.
Hoge EA, Bui E, Mete M, et al. · JAMA Psychiatry 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Trial of Psilocybin versus Escitalopram for Depression.
Carhart-Harris R, Giribaldi B, Watts R, et al. · N Engl J Med 2021 · Clinical Trial, Phase II, Comparative Study
- Escitalopram versus other antidepressive agents for major depressive disorder: a systematic review and meta-analysis.
Yin J, Song X, Wang C, et al. · BMC Psychiatry 2023 · Meta-Analysis, Systematic Review
- New generation antidepressants for depression in children and adolescents: a network meta-analysis.
Hetrick SE, McKenzie JE, Bailey AP, et al. · Cochrane Database Syst Rev 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Increased global integration in the brain after psilocybin therapy for depression.
Daws RE, Timmermann C, Giribaldi B, et al. · Nat Med 2022 · Clinical Trial, Phase II, Randomized Controlled Trial
- Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis.
Hsu TW, Tsai CK, Kao YC, et al. · BMJ 2024 · Systematic Review, Comparative Study
Sponsor: Almatica
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.